Ricevi le ultime notizie sulle azioni Liquidia con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di LQDA

Ultime notizie per

LIQUIDIA CORP

Liquidia

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Liquidia Corp

Health Care

Press Releases

General

U.S. FDA Approves Liquidia's YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

News

Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference

Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD

Financing

Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™

Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025

Earnings

Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference

Liquidia Announces Poster Presentations at the  Pulmonary Hypertension Professional Association (PHPN) Symposium

Small Cap

Liquidia to Present Clinical Data from ASCENT Trial at the CHEST 2025 Annual Meeting

Liquidia Corporation to Host R&D Day in New York City on October 28, 2025

LQDA

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

ANI Pharmaceuticals

Avadel Pharmaceuticals plc - Ordinary Share

Avadel Pharmaceuticals

BGM Group

Bausch Health Companies Inc. Common Stock

Bausch Health Companies

Belite Bio, Inc - American Depositary Shares

Belite Bio

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Harmony Biosciences Holdings, Inc. - Common Stock

Harmony Biosciences Hldgs

Harrow

Indivior

LENZ Therapeutics

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Ocular Therapeutix

Organon

Phibro Animal Health Corporation - Class A Common Stock

Phibro Animal Health

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pharvaris

Perrigo

Supernus Pharmaceuticals, Inc. - Common Stock

Supernus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. - Common Stock

Tarsus Pharmaceuticals

Tilray Brands

Xeris Biopharma Holdings, Inc. - Common Stock

Comments

Liquidia Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO